The trial, funded by the Biomedical Advanced Development Authority and the National Institutes of Health, will test the vaccine’s safety, efficacy and immunogenicity.
Test sites are in the U.S., Peru and Chile. AstraZeneca said it is looking for people who are healthy or who have stable underlying medical conditions, such as HIV. Patients will receive two doses of the vaccine four weeks apart, and results are expected later this year.
If the trials are successful and the vaccine is approved for use, “we will work hard to make it globally available in a fair and equitable manner as rapidly as possible,” said Mene Pangalos, AstraZeneca’s executive vice president of biopharmaceuticals research and development.
Read the full news release here.
More articles on pharmacy:
Westerly Hospital opens $4M pharmacy
13 exec moves affecting the pharma industry
Mylan recalls 2 drugs after label mix-up
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
